Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, PDT, LIC

OrthoVentions Invests in Motio[OV] to Develop 3D Printed Implant and Instruments to Treat Joint Arthritis of the Big Toe


ATLANTA, March 8, 2024 /PRNewswire/ -- OrthoVentions LLC today announced its investment in MotioOV, an early-stage company created in partnership with the Hospital for Special Surgery (HSS). MotioOV is developing a novel 3D printed implant and custom instruments to address stiffness and pain associated with arthritis of the first metatarsophalangeal (MTP) joint.

Under the terms of the investment, the company will be funded to complete product development and an initial commercial launch targeting the unmet clinical need of providing a functional MTP joint implant that reduces pain and preserves motion rather than the sub-optimal treatment of joint fusion. The solution under development will consist of various implant sizes and single-use instruments customized to complete total joint arthroplasty. Complaints of arthritic toe pain account for 20-30 percent of all patient visits to foot and ankle surgeon's practice.

"MotioOV is based on the fundamental understanding of the anatomy and associated forces of the MTP joint in an arthritic joint to invoke the design of an implant that minimizes insult to the bone and surrounding soft tissues while promoting stability," said Dr Holly Johnson, Co-Founder of MotioOV and an orthopedic foot and ankle surgeon at HSS. Dr. Constantine Demetracopoulos, an orthopedic foot and ankle surgeon at HSS and Co-Founder of MotioOV added, "We have taken a comprehensive approach combining image-driven design, additive manufacturing to optimize bone in-growth and procedure-specific instruments to deliver an efficient and reproducible surgical plan."

Jagi Gill, Founder and Managing Director of OrthoVentions, said, "The partnership with Doctors Johnson and Demetracopoulos brings best-in-class surgical experience in fore-foot and total joint arthroplasty to lead the design of our complete solution of implant and instrumentation leveraging the expertise of our product development partners. Arthritis of the MTP joint is a growing clinical burden driven by the aging population with no viable motion preserving option."

About OrthoVentions:
OrthoVentions LLC is a dedicated healthcare fund collaborating with the Hospital for Special Surgery to identify and develop novel technologies developed by their premiere musculoskeletal surgeons. The principals at OrthoVentions bring a strong track record as founders and operators of medical technologies companies with a rich experience in developing and commercializing compelling healthcare solutions. (www.orthoventions.com)

Contact:
Rom Papadopoulos
Chief Financial Officer
OrthoVentions LLC
[email protected]

SOURCE OrthoVentions LLC


These press releases may also interest you

at 02:30
111, Inc. ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for...

at 02:30
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports many presentations including new RefluxStoptm real-world data from over 200 patients at five hospitals across Europe, were presented in...

at 02:17
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 02:05
Genflow...

at 02:00
Leading scientists, philanthropists, and policymakers from around the world are coming together in Denmark at the Global Science Summit, hosted by the Novo Nordisk Foundation as part of the organisation's 100-year anniversary. The goal is to explore...

at 01:00
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on...



News published on and distributed by: